Fig 1.
A total of 137 patients with an elevated AFP level without any malignancy, ovarian teratoma, liver cirrhosis, chronic hepatitis, or elevated serum aspartate aminotransferase or alanine aminotransferase level above the upper normal limit of 40 IU/mL were compared with the hemangioma control group who had normal serum AFP levels. To analyze adiposity, 45 patients with non-enhanced CT images in the elevated AFP level group were compared to 90 patients with non-enhanced CT images in the hemangioma control group.
Table 1.
Baseline characteristics of the case group with elevated AFP in comparison with the control group.
Table 2.
Variables associated with elevated AFP >7 ng/mL.
Fig 2.
Longitudinal follow-up of AFP in the case group.
The Median follow-up period was 12.9 months. No patients had newly developed malignancy or liver cirrhosis. AFP level stayed stable and there was no significant change over time among patients during follow-up.
Table 3.
Baseline characteristics of the case group in comparison with the control group with CT—a cross-sectional study.
Table 4.
Variables associated with elevated AFP >7 ng/mL in patients with CT.